Security key
45826J105
Intellia Therapeutics, Inc. - COMMON STOCK (NTLA)
CUSIP: 45826J105
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 104,167,644
- Total 13F value
- $1,798,715,383
- Share change
- +5,026,180
- Put/Call ratio
- 48%
- SEC-reported price per share
- $17.27
- Number of holders
- 280
- Value change
- +$103,219,618
- Number of buys
- 144
- Number of sells
- 115
- Shares outstanding
- 135,808,632
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
280
Top holders
10
NTLA full security history
Ownership snapshot
Full 13F holder table
Intellia Therapeutics, Inc. SEC filings
Intellia Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of NTLA - Intellia Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
ARK Investment Management...
Comparable rows
15/15
Latest evidence
30 Jun 2025
13F
13D/G
Lead comparable stake: 8.2%
13D/G row: BlackRock, Inc.
Showing 1-6 of 15 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 8.2%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
8.2%
ARK Investment Management LLC
9.6%
VANGUARD GROUP INC
8%
MORGAN STANLEY
3%
STATE STREET CORP
3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
8.2%
from 13D/G
|
$94,054,899
10,027,175 shares
|
— | 30 Jun 2025 |
| ARK Investment Management LLC |
13F
Company
|
9.6%
|
$122,107,675
13,017,876 shares
|
— | 30 Jun 2025 |
| VANGUARD GROUP INC |
13F
Company
|
8%
|
$101,793,346
10,852,169 shares
|
— | 30 Jun 2025 |
| MORGAN STANLEY |
13F
Company
|
3%
|
$38,616,160
4,116,861 shares
|
— | 30 Jun 2025 |
| STATE STREET CORP |
13F
Company
|
3%
|
$37,888,493
4,039,285 shares
|
— | 30 Jun 2025 |
| REGENERON PHARMACEUTICALS, INC. |
13F
Company
|
2.7%
|
$34,734,093
3,702,995 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
280
Shares
104,167,644
Rows available
280
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
277
Q3 2025 holders
280
Holder diff
3
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|